Ovid Therapeutics (OVID) Cash from Financing Activities (2016 - 2026)

Ovid Therapeutics has reported Cash from Financing Activities for 11 years, with the latest figure at $89.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 684376.92% year-over-year to $89.0 million; the trailing twelve-month figure through Mar 2026 stood at $164.2 million (up 40238.08% YoY), and the FY2025 full-year result was $75.2 million, up 11991.16% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $89.0 million, up from $75.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $89.0 million in Q1 2026, with the low at -$43599.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $13.0 million across 5 years, with a median of $109549.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 139.93% — and 2026, when it soared 684376.92%.
• Ovid Therapeutics' Cash from Financing Activities stood at -$43599.0 in 2022, then surged by 68984.61% to $30.0 million in 2023, then slumped by 99.87% to $38000.0 in 2024, then soared by 197739.47% to $75.2 million in 2025, then advanced by 18.36% to $89.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $89.0 million (Q1 2026), $75.2 million (Q4 2025), and $15000.0 (Q3 2025), per Business Quant data.